Blood immune cells predicted worse MS after a first attack
By MS Buddy ·
Summarized from Brain : a journal of neurology, Jun 2026 · PubMed. AI-generated summary. Not medical advice.
Observational study · people with MS, other inflammatory conditions, and healthy volunteers
Research by Emilie Dugast, David-Axel Laplaud and 32 colleagues at Nantes Université, the University of Florence and 2 other institutions in France, Italy, the United States and 1 other country.
Can blood immune cells at a first MS-like attack predict later MS severity?
Key Takeaway
At a first MS-like attack, higher levels of certain blood immune cells predicted a more severe MS course two years later.

What They Found
Researchers found a group of blood immune cells linked to relapsing MS. These cells increased around the time of relapses. At a first MS-like attack, higher levels predicted a more severe MS course two years later. Lab tests showed these cells could kill other cells without their usual trigger. The cells were also found in areas of MS damage in the brain.
Who Should Care and Why
The study examined people with relapsing MS, people at their first MS-like attack, healthy volunteers, and people with other inflammatory conditions affecting the nervous system. It focused on immune cells in the blood. Researchers also examined areas of MS damage in the brain. The findings link blood immune cells to both relapses and later MS severity. They may help researchers study an early way to predict how MS will progress.
Important Considerations
You cannot use this finding to predict your own MS course. The abstract does not report how many people took part or how accurately the blood finding predicted later severity. Researchers observed these links and ran lab tests; they did not test a treatment.
AI-generated summary — for informational purposes only, not medical advice
Read the original abstract
Published in Brain : a journal of neurology by et al.. Reproduced from the PubMed record.
Memory CD8+ T cells are central to multiple sclerosis (MS) and undergo clonal expansion, but disease-associated states remain incompletely defined. By single-cell profiling of circulating memory CD8+ T cells from patients with relapsing-remitting MS, healthy volunteers, and neuroinflammatory controls, we identified an MS-associated cytotoxic subset with NK-like features. These cells increase around relapse activity and belong to an oligoclonal reservoir. In an independent cohort sampled at the first clinical event, an elevated frequency of NK-like CD8+ T cells predicted an aggressive MS course two years later and was associated with a migratory/inflammatory program. Bulk and single-cell RNA-seq confirmed the NK-like transcriptional signature, and functional assays demonstrated TCR-independent cytotoxicity. Immunostaining and spatial transcriptomics revealed enrichment of these cells in MS lesions and a spatial association with macrophages/microglia. Together, our results identify a cytotoxic NK-like CD8+ T-cell subset that links peripheral inflammation to CNS lesions and may serve as an early biomarker of MS severity.
Categories
Explore more research
Related MS research

11/18/2026
An adjusted MRI scan found more veins within MS brain lesions in 17 people with MS. It improved scan
Read More
11/16/2026
A planned study will use detailed brain scans and blood tests to explore why relapsing-remitting MS
Read More
1/1/2026
After a car crash, brain and spine scans revealed signs of MS in an 18-year-old male. Further tests
Read More
11/14/2026
An opinion paper explains why MS brain scans can show tissue loss without proving nerve signal failu
Read More
11/15/2026
In 70 people with MS in Brazil, blood tests often showed signs of past viral exposure. Results did n
Read More
11/12/2026
In a study of 601 people in Japan after first optic nerve inflammation, some later had MS. Others ha
Read MoreNot all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.
